Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.

Frontiers in bioengineering and biotechnology·2026
Same author

Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

mAbs·2026
Same author

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Clinical therapeutics·2026
Same author

Resolving the Interference of Anti-CD38 Antibodies on Blood Compatibility Assays Using CD38 "Baitbodies" Approach.

Journal of immunology research·2026
Same author

Immunogenic <i>Streptococcus equi</i> cell surface proteins identified by ORFeome phage display.

mSphere·2025
Same author

Phage Display Derived Antibodies Against Antimicrobial Peptide FsPDF2 Reveal Stress Response in European Beech.

Plant biotechnology journal·2025

Related Experiment Video

Updated: May 19, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Human antibodies targeting CD30(+) lymphomas.

Xenia Wezler1, Michael Hust, Saskia Helmsing

  • 1Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Braunschweig, Germany.

Human Antibodies
|August 14, 2012
PubMed
Summary

Researchers developed new CD30-specific antibodies for lymphoma treatment. One antibody, SH313-B5, effectively inhibited lymphoma cell proliferation, showing promise for future immunotherapies targeting CD30-expressing tumors.

More Related Videos

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

Related Experiment Videos

Last Updated: May 19, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Lymphomas, including Hodgkin and Non-Hodgkin types, are often treated with chemotherapy and radiation, which can have significant side effects and high relapse rates.
  • Immunotherapy using monoclonal antibodies presents a promising alternative to overcome limitations of conventional treatments for malignant lymphomas.
  • The CD30 antigen is highly expressed on Hodgkin lymphomas and certain Non-Hodgkin lymphomas, making it an attractive target for antibody-based therapies.

Purpose of the Study:

  • To isolate and characterize novel CD30-specific antibodies for potential therapeutic applications in lymphoma treatment.
  • To evaluate the binding affinity, specificity, and internalization of newly developed antibodies against CD30-expressing lymphoma cells.
  • To assess the anti-proliferative efficacy of the lead antibody candidate in vitro.

Main Methods:

  • Phage display technology was employed to screen a human naïve antibody gene library for CD30-specific antibodies.
  • Recombinant antibodies were produced as single-chain variable fragments (scFv) and scFv-Fc fusion proteins.
  • Flow cytometry, confocal laser scanning microscopy, and proliferation assays were utilized to analyze antibody binding, cellular uptake, and functional activity.

Main Results:

  • Four novel CD30-specific antibodies were successfully isolated.
  • The recombinant antibodies demonstrated high specificity for both recombinant CD30 antigen and CD30-positive lymphoma cells.
  • The antibody clone SH313-B5 exhibited potent, dose-dependent inhibition of CD30-positive lymphoma cell proliferation (IC50 = 100 nM) via receptor-mediated endocytosis.

Conclusions:

  • The isolated CD30-specific antibodies, particularly SH313-B5, show significant potential as therapeutic agents for CD30-expressing lymphomas.
  • SH313-B5's ability to inhibit lymphoma cell proliferation warrants further investigation for clinical development.
  • These findings support the advancement of antibody-based immunotherapies for treating CD30-positive malignancies.